Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 7.2% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) dropped 7.2% during mid-day trading on Tuesday . The company traded as low as $0.28 and last traded at $0.29. Approximately 30,458,623 shares traded hands during mid-day trading, a decline of 56% from the average daily volume of 68,841,906 shares. The stock had previously closed at $0.31.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a report on Wednesday, January 1st. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Down 7.2 %

The firm has a fifty day moving average of $0.24 and a 200-day moving average of $0.34. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The firm has a market cap of $54.20 million, a P/E ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. On average, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.